OBJECTIVE -Insulin resistance is a key characteristic of first-degree relatives of patients with type 2 diabetes. We therefore treated young, glucose-tolerant relatives with the insulin action enhancer troglitazone in order to determine the effects on insulin sensitivity, glucose metabolism, and glycogen synthase activity.RESEARCH DESIGN AND METHODS -Relatives were randomized in a doubleblind manner and treated for 12 weeks with either 200 mg troglitazone or placebo. Before and after treatment, an oral glucose tolerance test (OGTT) and a euglycemic-hyperinsulinemic clamp (40 mU ⅐ m Ϫ2 ⅐ min Ϫ1 ) were performed, including 3-3 H glucose infusion, glycolytic flux calculations, indirect calorimetry, and muscle biopsies. CONCLUSIONS -In glucose-tolerant first-degree relatives, treatment with troglitazone improved insulin sensitivity almost 50%, primarily due to increased glucose storage. It is suggested that the use of insulin action enhancers can be especially valuable in this group of subjects with a known high risk for developing type 2 diabetes.
RESULTS
Diabetes Care 27:148 -154, 2004T he pathophysiology underlying type 2 diabetes is complex and believed to involve both genetically programmed factors and environmental influences, such as high-fat diets and sedentary lifestyles (1,2). Irrespective of the etiological process leading to type 2 diabetes, the phenotypically most common form is characterized by a marked reduction in insulin-stimulated glucose uptake, predominantly in skeletal muscle, and a relative insulin deficiency (1,2).Insulin resistance has also been demonstrated in healthy first-degree relatives of type 2 diabetic patients and has therefore been proposed as an early marker of abnormal glucose metabolism (3,4). Moreover, premature atherosclerosis has been linked to insulin resistance; therefore treatments that improve insulin action seem pivotal in order to prevent or postpone the disease process.Troglitazone, now superseded by rosiglitazone and pioglitazone, was the first of a new class of antidiabetic drugs, the thiazolidinediones (also known as glitazones), with insulin-sensitizing actions. The molecular target of these agents is thought to include the nuclear transcription factor peroxisome proliferatoractivated receptor-␥ (PPAR␥), which regulates numerous genes involved in adipocyte differentiation and lipid and glucose metabolism (5). PPAR␥ is mainly expressed in adipose tissue and, to a lesser extent, in muscle (6). The effects of PPAR␥ agonists on insulin sensitivity in skeletal muscle could therefore be indirect, involving adipose tissue PPAR␥ stimulation and leading to reductions in circulating and intramyocellular lipid levels (7-11) or alterations in the secretion of factors that modulate skeletal muscle insulin action (12)(13)(14). Alternatively, PPAR␥ agonists exhibit local (direct) intramyocellular actions, as suggested in some studies (10,15,16), although it remains to be investigated whether PPAR␥ agonists regulate gene expression in muscle by direct receptor activation.Several cl...